Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | IDH1 | O75874 | 8/20 | 0.39 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3759047 | 1.00 | SLC18A3 (0.42) | SLC18A3SIGMAR1IDH1NSD3HPGD | |
| SCHEMBL3759045 | 1.00 | SLC18A3 (0.42) | SLC18A3SIGMAR1IDH1NSD3HPGD | |
| SCHEMBL4598376 | 0.84 | HTR2C (0.50) | NSD3KMT2A | |
| SCHEMBL4598369 | 0.84 | HTR2C (0.50) | NSD3KMT2A | |
| SCHEMBL4597972 | 0.84 | HTR6 (0.41) | SIGMAR1HPGDHTR6 | |
| SCHEMBL4597968 | 0.84 | HTR6 (0.41) | SIGMAR1HPGDHTR6 | |
| SCHEMBL4597196 | 0.82 | SLC18A3 (0.42) | SLC18A3SIGMAR1NSD3HPGDKMT2A | |
| SCHEMBL4597202 | 0.82 | SLC18A3 (0.42) | SLC18A3SIGMAR1NSD3HPGDKMT2A | |
| SCHEMBL4552097 | 0.82 | CCR5 (0.41) | AVPR1A | |
| SCHEMBL4598234 | 0.81 | GABRA1 (0.36) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2005-06-30 | — | — | US | disclosed |
| WO-2003037271-A2 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS,INC. (US) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | CCR8, CCL11, CCR5 | SLC18A3 574/4885SIGMAR1 525/4885IDH1 4358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.